• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Preliminary evidence of CAR T-cell therapy activity in vitreoretinal lymphomas: An LOC network study.

作者信息

Pivert Cécile, Toutée Adélaïde, Parizot Christophe, Malaise Denis, Matet Alexandre, Touitou Valérie, Garff-Tavernier Magali Le, Roos-Weil Damien, Touhami Sarah, Azar Nabih, Boussen Ines, Morel Véronique, Uzunov Madalina, Bravetti Clotilde, Metz Carole, Todesco Eve, Sterlin Delphine, Soussain Carole, Tarhi Kahina Ouis, Besançon Anne, Hoang-Xuan Khê, Choquet Sylvain, Houillier Caroline, Baron Marine

机构信息

Department of Clinical Haematology, AP-HP, Hôpital Pitié-Salpêtrière Sorbonne Université Paris France.

Department of Ophthalmology, AP-HP, Hôpital Pitié-Salpêtrière Sorbonne Université Paris France.

出版信息

Hemasphere. 2025 Aug 25;9(8):e70208. doi: 10.1002/hem3.70208. eCollection 2025 Aug.

DOI:10.1002/hem3.70208
PMID:40862223
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12375968/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8ef/12375968/a5939b2d4bda/HEM3-9-e70208-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8ef/12375968/a5939b2d4bda/HEM3-9-e70208-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8ef/12375968/a5939b2d4bda/HEM3-9-e70208-g001.jpg

相似文献

1
Preliminary evidence of CAR T-cell therapy activity in vitreoretinal lymphomas: An LOC network study.嵌合抗原受体T细胞疗法治疗玻璃体视网膜淋巴瘤的初步证据：一项LOC网络研究
Hemasphere. 2025 Aug 25;9(8):e70208. doi: 10.1002/hem3.70208. eCollection 2025 Aug.
2
Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.与弥漫性大B细胞淋巴瘤相比，嵌合抗原受体T细胞疗法治疗高级别B细胞淋巴瘤的疗效：加权比较分析
Blood Adv. 2025 Aug 5. doi: 10.1182/bloodadvances.2025016117.
3
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.既往CAR T细胞疗法对复发或难治性B细胞淋巴瘤患者中mosunetuzumab疗效的影响。
Blood Adv. 2025 Feb 25;9(4):696-703. doi: 10.1182/bloodadvances.2024013640.
4
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.替雷利珠单抗自体白细胞介素用于复发或难治性B细胞恶性肿瘤：一项开放标签、多中心、1/2期研究的结果
Lancet Haematol. 2025 Apr;12(4):e282-e293. doi: 10.1016/S2352-3026(24)00377-6. Epub 2025 Mar 13.
5
Nursing Management in Pediatric Patients Undergoing Chimeric Antigen Receptor T (CAR-T) Cell Therapy: A Systematic Literature Review.儿科患者嵌合抗原受体 T（CAR-T）细胞治疗的护理管理：系统文献回顾。
Semin Oncol Nurs. 2023 Oct;39(5):151478. doi: 10.1016/j.soncn.2023.151478. Epub 2023 Aug 4.
6
K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies.基于K12配体的CAR-T细胞疗法治疗CD7阳性T细胞恶性肿瘤
Mol Ther Oncol. 2025 Apr 29;33(2):200988. doi: 10.1016/j.omton.2025.200988. eCollection 2025 Jun 18.
7
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
8
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.CD22 导向的 CAR T 细胞疗法治疗 CD19 导向的 CAR T 细胞疗法后进展的大 B 细胞淋巴瘤：一项剂量探索性 1 期研究。
Lancet. 2024 Jul 27;404(10450):353-363. doi: 10.1016/S0140-6736(24)00746-3. Epub 2024 Jul 9.
9
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.抗 CD19 CAR-T 细胞疗法在老年患者中的应用：GETH-TC/GELTAMO 的多中心真实世界经验。
Transplant Cell Ther. 2024 Oct;30(10):988.e1-988.e11. doi: 10.1016/j.jtct.2024.06.022. Epub 2024 Jul 26.
10
An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL.抗 CD19/CTLA-4 开关可提高针对 CD80/86 上调的 DLBCL 的 CAR T 细胞的疗效和选择性。
Cell Rep Med. 2024 Feb 20;5(2):101421. doi: 10.1016/j.xcrm.2024.101421. Epub 2024 Feb 9.

本文引用的文献

1
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.孤立性玻璃体视网膜淋巴瘤患者的大剂量化疗联合自体造血干细胞移植：一项LOC网络研究
Bone Marrow Transplant. 2025 Mar;60(3):297-304. doi: 10.1038/s41409-024-02477-y. Epub 2024 Nov 19.
2
CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.嵌合抗原受体 T 细胞疗法可诱导复发原发性中枢神经系统淋巴瘤的高缓解率：LOC 网络的真实结果。
Am J Hematol. 2024 Jul;99(7):1240-1249. doi: 10.1002/ajh.27316. Epub 2024 Apr 8.
3
PRESUMPTIVE RECURRENCE OF INTRAOCULAR LYMPHOMA DESPITE CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY.
嵌合抗原受体 T 细胞治疗后眼内淋巴瘤的推定复发。
Retin Cases Brief Rep. 2023 Sep 1;17(5):562-566. doi: 10.1097/ICB.0000000000001246.
4
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study.嵌合抗原受体T细胞疗法治疗合并中枢神经系统受累的大B细胞淋巴瘤的真实世界结果：一项GLA/DRST研究
Blood Adv. 2023 Sep 26;7(18):5316-5319. doi: 10.1182/bloodadvances.2023010336.
5
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.嵌合抗原受体 T 细胞过继免疫治疗后原发性和继发性中枢神经系统淋巴瘤的神经毒性及处理。
Neuro Oncol. 2023 Dec 8;25(12):2239-2249. doi: 10.1093/neuonc/noad118.
6
CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes.中枢神经系统淋巴瘤的嵌合抗原受体T细胞疗法：血液和脑脊液生物学及治疗结果
Haematologica. 2023 Dec 1;108(12):3485-3490. doi: 10.3324/haematol.2023.282875.
7
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.原发性脑淋巴瘤的孤立性眼内复发：一项LOC网络研究。
Hematol Oncol. 2022 Dec;40(5):976-986. doi: 10.1002/hon.3044. Epub 2022 Jul 14.
8
Acute Lymphoblastic Leukemia Relapse Limited to the Anterior Chamber of the Eye and Treated with Novel CAR T-Cell Therapy.局限于眼前房的急性淋巴细胞白血病复发并采用新型嵌合抗原受体T细胞疗法进行治疗。
Case Rep Ophthalmol. 2021 Dec 28;12(3):994-1001. doi: 10.1159/000521200. eCollection 2021 Sep-Dec.
9
CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network.嵌合抗原受体T细胞疗法治疗原发性中枢神经系统淋巴瘤：法国LOC网络的临床经验
Blood. 2022 Feb 3;139(5):792-796. doi: 10.1182/blood.2021012932.
10
Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study.基于静脉注射大剂量甲氨蝶呤的全身治疗在原发性孤立性眼内及眼后段淋巴瘤治疗中的应用：一个 LOC 网络研究。
Am J Hematol. 2021 Jul 1;96(7):823-833. doi: 10.1002/ajh.26199. Epub 2021 May 3.